PBL Gains Approval to Advance Next Generation Anthrax Vaccine
Porton Biopharma Ltd (PBL) has announced that it has signed a modification to its contract with the US National Institute of Health's National Institute of Allergy and Infectious Diseases (NIAID) to advance a next generation intra-nasal anthrax vacci …
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Allergy | Allergy & Immunology | Anthrax | Anthrax Vaccine | Contracts | Infectious Diseases | National Institutes of Health (NIH) | Pharmaceuticals | Vaccines